DSS’s Impact BioMedical to Research Plant-Based Preservation Booster in Collaboration with Thomas Swan Co.
July 27 2021 - 8:00AM
Impact BioMedical, Inc., a wholly-owned subsidiary of Document
Security Systems Inc. (NYSE American: DSS), today announced with
its scientific research partner Global Research and Discovery Group
Sciences, GRDG, a collaboration with Thomas Swan Co., to research
its plant-based preservation booster, Procombin.
“This collaboration with the Thomas Swan & Co., will
extensively test the effectiveness and fitness of Procombin and
expand the possibilities of its real-world applications of a
plant-based preservation booster,” said Daryl Thompson, Impact
BioMedical’s Director of Scientific Initiatives, and founder of
GRDG Sciences, LLC.
Founded in England in 1926, Thomas Swan & Co. has developed
a reputation for custom research and development with companies
like Impact Biomedical, to use cutting-edge scientific techniques
to test and expand the possibilities of developed substances. The
Procombin collaboration will be with Swan Chemical, the New
Jersey-based U.S. subsidiary of Thomas Swan & Co.
“We are excited to enter into this phase of development for
Procombin. Our early experimental studies have indicated that
Procombin may be of use as a preservation booster. Preservation
boosters, enhance products that are used every day, lengthening
product shelf life, and boosting the quality of life for people
around the world,” said Mr. Chan Heng Fai, Chairman of DSS.
Introducing an effective, sustainable booster to the current
stable of preservatives could be a huge boost to the whole
preservation market, according to Ray Fahmy, Swan Chemical’s
president.
"Personal care, as well as household & institutional
cleaning formulators have had to manage/struggle with an
ever-shrinking portfolio of safe and effective preservatives and
preservation boosters." Fahmy said.
Procombin was developed as a plant-derived preservation booster
in an ongoing attempt to use plant-based solutions to increase the
effectiveness of antibiotics and antimicrobial agents. The new
collaborative research will study Procombin for use in multiple
different applications, including household, institutional and
personal care products. The research will focus on use in a wide
range of consumer products, ranging from household cleaning
products to shampoos and conditioners.
“We are encouraged with the early development of Procombin which
is further demonstration of our intent to continue to evaluate
emerging technologies through Impact Biomedical and pursue those
which can deliver new solutions to our customers.” said Frank
Heuszel, the President of Impact Biomedical.
About Thomas Swan
- Thomas Swan & Co. Ltd. was founded in the UK in 1926 and
remains an independent family owned and run performance and
specialty chemical manufacturing company.
- The Company turns over approximately £37m per annum, employs
170 people and exports to over 80 countries from its manufacturing
headquarters in the North East of England. It has offices in the
USA and China.
- The business is divided into 3 divisions which include
Performance Chemicals, Custom Manufacture and Advanced
Materials.
- Thomas Swan products include graphene, biocides used in common
household disinfectants, rubber additives for the tyre industry and
plant derived resins used in printing inks.
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
Impact BioMedical strives to leverage its scientific know-how and
intellectual property rights to provide solutions that have been
plaguing the biomedical field for decades. By tapping into the
scientific expertise of GRDG Sciences, LLC, Impact BioMedical
pledges to undertake a concerted effort in the R&D, drug
discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno related diseases.
For more information on Impact BioMedical visit
http://impbio.com/.
About Document Security Systems, Inc.DSS is a
multinational company operating businesses focused on brand
protection technology, blockchain security, direct marketing,
healthcare, real estate, and securitized digital assets. Its
business model is based on a distribution sharing system in which
shareholders will receive shares in its subsidiaries as DSS
strategically spins them out into IPOs. Its historic business
revolves around counterfeit deterrent and authentication
technologies, smart packaging, and consumer product engagement. DSS
is led by its Chairman, Mr. Fai Chan, a highly successful global
business veteran of more than 40 years specializing in corporate
transformation while managing risk. He has successfully
restructured more than 35 corporations with a combined value of $25
billion.
For more information on DSS visit
http://www.dsssecure.com.Investor Contact:Dave Gentry,
CEORedChip Companies Inc.407-491-4498Dave@redchip.com
Safe Harbor DisclosureThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Jul 2023 to Jul 2024